Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme
View / Open Files
Authors
Brenton, JD
Publication Date
2018Journal Title
ESMO Open
ISSN
2059-7029
Publisher
BMJ Publishing Group
Volume
3
Issue
6
Number
e000408
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Brenton, J. (2018). Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3 (6. e000408) https://doi.org/10.1136/esmoopen-2018-000408
Abstract
Introduction
Phase I of the Cancer Research UK Stratified Medicine Programme (SMP1) was designed to roll out molecular pathology testing nationwide at the point of cancer diagnosis, as well as facilitate an infrastructure where surplus cancer tissue could be used for research. It offered a non-trial setting to examine common UK cancer genetics in a real-world context.
Methods
A total of 26 sites in England, Wales and Scotland, recruiting samples from 7,814 patients for genetic examination between 2011-2013. Tumor types involved were breast, colorectal, lung, prostate, ovary cancer and malignant melanoma. Centralised molecular testing of surplus material from resections or biopsies of primary/metastatic tissue was performed, with samples examined for 3-5 genetic alterations deemed to be of key interest in site-specific cancers by National Cancer Research Institute Clinical Study groups.
Results
10,754 patients (98% of those approached) consented to participate, from which 7,814 tumor samples were genetically analysed. In total, 53% had at least one genetic aberration detected. From 1885 lung cancer patients, KRAS mutation was noted to be highly prevalent in adenocarcinoma (37%). In breast cancer (1873 patients), there was a striking contrast in TP53 mutation incidence between patients with ductal cancer (27.3%) and lobular cancer (3.4%). Vast inter-tumor heterogeneity of colorectal cancer (1550 patients) was observed , including myriad double and triple combinations of genetic aberrations. Significant losses of important clinical information included smoking status in lung cancer and loss of distinction between low and high grade serous ovarian cancers.
Conclusion
Nationwide molecular pathology testing in a non-trial setting is feasible. The experience with SMP1 has been used to inform ongoing CRUK flagship programmes such as the CRUK National Lung MATRIX trial and TRACERx.
Sponsorship
Funding for the Stratified Medicine Programme is acknowledged from Cancer Research UK and programme founding partners AstraZeneca and Pfizer. For hosting the Stratified Medicine Programme data, thanks to the National Cancer Registration Service Eastern Office, Jim Davies and Steve Harris at the University of Oxford Department of Computer Science. AGN was supported by the National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. PJ, ES and CL have all been employed by Cancer Research UK in the past. FB was supported by Cancer Research UK Lung Cancer Centre of Excellence Funding. WAW was supported by Lothian NRS BioResource. SP acknowledges NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR. NPW is supported by Yorkshire Cancer Research. KGB is supported by a NHS Research Scotland Senior Fellowship.
Funder references
Cancer Research UK (CB4150)
Cancer Research UK (C14303/A17197)
Identifiers
External DOI: https://doi.org/10.1136/esmoopen-2018-000408
This record's URL: https://www.repository.cam.ac.uk/handle/1810/283622
Rights
Attribution-NonCommercial 4.0 International
Licence URL: http://creativecommons.org/licenses/by-nc/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The following licence files are associated with this item: